EP3544616A4 - Lyophilized pharmaceutical compositions of dalbavancin - Google Patents

Lyophilized pharmaceutical compositions of dalbavancin Download PDF

Info

Publication number: EP3544616A4
Authority: EP; European Patent Office
Prior art keywords: dalbavancin; pharmaceutical compositions; lyophilized pharmaceutical; lyophilized; compositions
Prior art date: 2016-11-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP17873284.8A

Other languages

German (de)

French (fr)

Other versions

EP3544616A1 (en

Inventor

Mitesh Natavarlal Patel

Mafatlal Tribhovandas DAVE

Beena Pourusashap ANKLESARIA

Pranavkumar Jayesh Choksi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Gufic Biosciences Ltd

Original Assignee

Gufic Biosciences Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-11-23

Filing date

2017-11-21

Publication date

2020-12-09

2017-11-21 Application filed by Gufic Biosciences Ltd filed Critical Gufic Biosciences Ltd

2019-10-02 Publication of EP3544616A1 publication Critical patent/EP3544616A1/en

2020-12-09 Publication of EP3544616A4 publication Critical patent/EP3544616A4/en

Status Withdrawn legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP17873284.8A 2016-11-23 2017-11-21 Lyophilized pharmaceutical compositions of dalbavancin Withdrawn EP3544616A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN201621039995		2016-11-23
PCT/IN2017/050546 WO2018096556A1 (en)	2016-11-23	2017-11-21	Lyophilized pharmaceutical compositions of dalbavancin

Publications (2)

Publication Number	Publication Date
EP3544616A1 EP3544616A1 (en)	2019-10-02
EP3544616A4 true EP3544616A4 (en)	2020-12-09

Family

ID=62194924

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP17873284.8A Withdrawn EP3544616A4 (en)	2016-11-23	2017-11-21	Lyophilized pharmaceutical compositions of dalbavancin

Country Status (3)

Country	Link
EP (1)	EP3544616A4 (en)
RU (1)	RU2019119405A (en)
WO (1)	WO2018096556A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2023211501A1 (en) *	2022-04-26	2023-11-02	Hikma Pharmaceuticals Usa Inc.	Stable, ready-to-administer aqueous formulations of dalbavancin
US20240139282A1 (en) *	2022-10-12	2024-05-02	Xellia Pharmaceuticals Aps	Liquid dalbavancin compositions
WO2024079224A1 (en) *	2022-10-12	2024-04-18	Xellia Pharmaceuticals Aps	Liquid dalbavancin composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20090298749A1 (en) *	2002-11-18	2009-12-03	Vicuron Pharmaceuticals Inc.	Dalbavancin compositions for treatment of bacterial infections
WO2014085526A1 (en) *	2012-11-29	2014-06-05	Insmed Incorporated	Stabilized vancomycin formulations
WO2016071495A1 (en) *	2014-11-06	2016-05-12	Xellia Pharmaceuticals Aps	Glycopeptide compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7119061B2 (en) *	2002-11-18	2006-10-10	Vicuron Pharmaceuticals, Inc.	Dalbavancin compositions for treatment of bacterial infections

2017
- 2017-11-21 RU RU2019119405A patent/RU2019119405A/en not_active Application Discontinuation
- 2017-11-21 EP EP17873284.8A patent/EP3544616A4/en not_active Withdrawn
- 2017-11-21 WO PCT/IN2017/050546 patent/WO2018096556A1/en unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20090298749A1 (en) *	2002-11-18	2009-12-03	Vicuron Pharmaceuticals Inc.	Dalbavancin compositions for treatment of bacterial infections
WO2014085526A1 (en) *	2012-11-29	2014-06-05	Insmed Incorporated	Stabilized vancomycin formulations
WO2016071495A1 (en) *	2014-11-06	2016-05-12	Xellia Pharmaceuticals Aps	Glycopeptide compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2018096556A1 *

Also Published As

Publication number	Publication date
RU2019119405A (en)	2020-12-25
RU2019119405A3 (en)	2020-12-30
EP3544616A1 (en)	2019-10-02
WO2018096556A1 (en)	2018-05-31

Legal Events

Date	Code	Title	Description
2018-06-12	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2019-08-30	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2019-08-30	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2019-10-02	17P	Request for examination filed	Effective date: 20190624
2019-10-02	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2019-10-02	AX	Request for extension of the european patent	Extension state: BA ME
2020-02-26	DAV	Request for validation of the european patent (deleted)
2020-02-26	DAX	Request for extension of the european patent (deleted)
2020-11-04	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031704000 Ipc: A61K0009190000
2020-12-09	A4	Supplementary search report drawn up and despatched	Effective date: 20201110
2020-12-09	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/7042 20060101ALI20201104BHEP Ipc: A61K 47/18 20170101ALI20201104BHEP Ipc: A61K 38/14 20060101ALI20201104BHEP Ipc: A61K 9/19 20060101AFI20201104BHEP
2023-01-27	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN
2023-03-01	18W	Application withdrawn	Effective date: 20230125

Publication	Publication Date	Title
EP3426348A4 (en)	2019-11-20	3-desoxy derivative and pharmaceutical compositions thereof
EP3641771A4 (en)	2020-12-16	Pharmaceutical compositions
EP3563863A4 (en)	2020-10-14	Lyophilized preparation
EP3316685A4 (en)	2019-03-13	Lyophilized pharmaceutical compositions
EP3102555A4 (en)	2017-06-14	Compositions of compounds and uses thereof
EP3582777A4 (en)	2020-12-23	Pharmaceutical composition of apixaban
EP3310439A4 (en)	2019-02-20	Pharmaceutical compositions for anesthesiological applications
AU2018302170A1 (en)	2020-01-30	Pharmaceutical compositions comprising entrectinib
EP3581183A4 (en)	2020-12-09	Tumor-treating pharmaceutical composition
EP3583943A4 (en)	2020-12-30	Pharmaceutical composition
EP3202759A4 (en)	2018-05-09	Alpha-aminoamide derivative compound and pharmaceutical composition comprising same
EP3389633A4 (en)	2019-08-07	Pharmaceutical compositions comprising phenylaminopyrimidine derivative
EP3524250A4 (en)	2020-05-20	Pharmaceutical composition
EP3544616A4 (en)	2020-12-09	Lyophilized pharmaceutical compositions of dalbavancin
EP3720844A4 (en)	2021-08-11	Drug compositions
EP3646867A4 (en)	2021-03-24	Pharmaceutical composition
EP3493808A4 (en)	2020-04-01	Pharmaceutical compositions of ibrutinib
EP3496714A4 (en)	2020-04-22	Drug compositions
EP3503885A4 (en)	2020-03-25	Pharmaceutical composition and methods of uses
EP3363288A4 (en)	2019-07-03	Composition for destruction of microalgae or sphaerocarpus
EP3319930A4 (en)	2019-04-10	Methods and compositions for the stabilizaton of proteins
EP3288933A4 (en)	2019-01-16	Oxindole compounds and pharmaceutical compositions thereof
EP3244895A4 (en)	2018-07-25	Novel pharmaceutical composition
EP3646863A4 (en)	2021-03-24	Pharmaceutical composition
EP3616722A4 (en)	2021-01-06	Pharmaceutical composition